Gilead Sciences (GILD): Earnings Whisper

Gilead Sciences Inc. (GILD) is scheduled to report earnings results for the second quarter of fiscal 2015 today after the close. The Street is looking for revenues of $7.58 billion, a 16% growth from $6.53 billion in the same period a year earlier. As far as EPS is concerned, analysts expect Gilead’s year-over-year profit to increase by 18.33% to $2.71. Meanwhile, calls for EPS of $2.92.

As a quick reminder, Gilead Sciences Inc. reported 1Q/15 EPS of $2.76, $0.48 better than the Street’s consensus estimate of $2.28. Revs came in at $7.59 billion versus the $6.81 billion consensus.

On valuation measures, Gilead Sciences Inc. shares are currently priced at 12.60x this year’s forecasted earnings. Ticker has a forward P/E of 9.93 and t-12 price-to-sales ratio of 6.03. EPS for the same period is $8.77.

In terms of share statistics, Gilead Sciences Inc. has a total of 1.47 billion shares outstanding with 0.59% held by insiders and 94.30% held by institutions. The stock’s short interest currently stands at 1.41%, bringing the total number of shares sold short to 20.61 million.

Over the past year, shares of Foster City, California-based biopharmaceutical company have traded between a low of $85.95 and a high of $123.37 and are now at $110.54. Shares are up 23.49% year-over-year and 17.70% year-to-date.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.